 |
|
A Promising Step Forward in Psoriasis Therapy
Robert S. Stern, MD
JAMA. 2003;290:3133-3135.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
About 4.5 million adults in the United States have psoriasis,1 a chronic, often uncomfortable and disfiguring disease typically lasting more than 30 years. Approximately half a million individuals find the disease a substantial problem in everyday life. Fewer than half of those affected by psoriasis find their treatment highly satisfactory.1
Although available treatment options for patients with severe psoriasis have changed little over nearly 20 years, psoriasis has recently become a focus for innovative therapies. With the development of monoclonal antibodies that alter immune function, 4 new products—2 antibodies that modulate T-cell functions (efalizumab and alefacept) and 2 tumor necrosis factor  inhibitors (infliximab and etanercept)—have demonstrated beneficial effects on moderate to severe psoriasis. In this issue of THE JOURNAL, Gordon et al2 report on the effect of efalizumab on psoriasis as measured by both physician and patient assessment. This and other studies demonstrate that efalizumab is . . . [Full Text of this Article]
Author Affiliations: Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Efalizumab for Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial
Kenneth B. Gordon, Kim A. Papp, Tiffani K. Hamilton, Patricia A. Walicke, Wolfgang Dummer, Nicole Li, Brian W. Bresnahan, and Alan Menter
JAMA. 2003;290(23):3073-3080.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Psoriasis
Madariaga et al.
NEJM 2005;353:848-850.
FULL TEXT
|
